Lilly's Pancreatic Enzyme Replacement Therapy Faces Advisory Committee Scrutiny
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Gastrointestinal Drugs panel's Jan. 12 review of Solpura (liprotamase) is likely to focus on robustness of efficacy results and relevant endpoints.